Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
October 23, 2023 08:00 ET
|
Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
ADC (Antibody Drug Conjugates) Markets, 2035
October 17, 2023 07:38 ET
|
Research and Markets
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of...
Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners
October 09, 2023 08:04 ET
|
The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
Antibody Drug Conjugates Market to increase by USD 34.7 Billion by 2032 || North America led with a 40% revenue share in 2022
September 25, 2023 09:23 ET
|
Market.Us
New York, Sept. 25, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Market.us, the Global Antibody Drug Conjugates Market size is expected to be worth around USD 34.7 Billion by 2032 from...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
August 24, 2023 11:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Antibody Drug Conjugate (ADC) Markets, 2035
August 24, 2023 06:33 ET
|
Research and Markets
Dublin, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key...
Global Antibody Drug Conjugate (ADC) Forecast to 2028 - Next-Generation ADCs Spurring Growth Opportunities
August 22, 2023 08:03 ET
|
Research and Markets
Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The report...
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
July 20, 2023 11:45 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the...
Global Cancer Antibody Drug Conjugates Market Outlook to 2029: Size, Drug Sales, Drug Dosage, Price, & Clinical Trials
June 16, 2023 06:28 ET
|
Research and Markets
Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Global Cancer Antibody Drug Conjugates Market Outlook 2029" report has been added to ResearchAndMarkets.com's offering.Global Cancer Antibody Drug...
Global Antibody Drug Conjugates Market to 2030: Rising Incidences of Cancer Worldwide Bolsters Growth
June 01, 2023 11:53 ET
|
Research and Markets
Dublin, June 01, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugates Market Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.The Global Antibody Drug...